New Delhi: Scientists have reported encouraging early results from the first human trial of an experimental HIV medicine that works in a completely new way. The drug, known as VH4524184, targets a human protein that HIV needs to reproduce, rather than attacking the virus directly. Researchers say the findings could pave the way for a new class of HIV treatments, although the medicine remains in the early stages of development.
The results come from a Phase 1 clinical trial involving healthy volunteers. While the study found the drug to be generally safe and suitable for once-daily dosing, it has not yet been tested in people living with HIV, meaning further research is required before it can be considered for clinical use.
New approach to HIV treatment
Unlike current antiretroviral medicines, which directly target different parts of the HIV virus, VH4524184 works by blocking a human protein that the virus depends on to make copies of itself.
By preventing HIV from using this protein, researchers hope the medicine can stop the virus from multiplying inside the body.
Scientists believe this novel mechanism may offer an alternative treatment strategy, particularly for people whose HIV has developed resistance to existing drugs.
The experimental medicine belongs to a completely new class of HIV therapies and represents a different scientific approach to controlling the infection.
Phase 1 trial shows encouraging safety profile
The first human study focused primarily on evaluating the safety of the medicine and understanding how it behaves inside the human body.
The Phase 1 clinical trial enrolled healthy adult volunteers rather than people diagnosed with HIV.
According to the researchers, the medicine was generally well tolerated during the study. Most reported side effects were mild, and no serious safety concerns were identified.
The trial also found that the drug remained in the body long enough to support once-daily dosing, an important consideration for long-term treatment if future trials prove successful.
The findings have been published in the journal Clinical Infectious Diseases.
Potential benefits over existing medicines
Current HIV treatment usually involves combinations of antiretroviral drugs that target viral enzymes such as reverse transcriptase, integrase and protease.
Because VH4524184 acts on a human protein instead of directly targeting the virus, researchers believe it may remain effective even if HIV develops resistance to some currently available medicines.
Scientists say developing drugs with different mechanisms of action is important because HIV can mutate over time, making some treatments less effective.
New therapeutic options could improve treatment outcomes for patients who have limited alternatives due to drug resistance.
Why the research matters
Modern antiretroviral therapy has transformed HIV from a fatal illness into a manageable chronic condition for many people.
With consistent treatment, most people living with HIV can now lead long and healthy lives. However, challenges such as drug resistance, side effects, treatment adherence, medicine interactions, stigma and access to healthcare continue to affect many patients.
Researchers involved in the study said there remains a need for innovative therapies that address these challenges while expanding available treatment options.
The study also contributes to scientists’ understanding of how HIV interacts with human cells, which may support the development of future therapies.
Not a cure, experts caution
Despite the promising findings, researchers emphasise that the medicine is not a cure for HIV.
The Phase 1 trial assessed only the drug’s safety and pharmacological properties in healthy volunteers. It did not evaluate its effectiveness in treating HIV infection.
The medicine must now undergo larger Phase 2 and Phase 3 clinical trials involving people living with HIV before regulators can determine whether it is safe and effective enough for approval.
Even if future studies are successful, VH4524184 would become an additional treatment option rather than replacing existing therapies or providing a cure.
For now, experts stress that people living with HIV should continue taking their prescribed antiretroviral medicines and consult healthcare professionals before considering any changes to their treatment.